Biblio
Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax. Clin Cancer Res. 2024.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024.
A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Adv. 2024.
A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024.
. Chimeric Antigen Receptor T Therapy for Adult B-Cell Acute Lymphoblastic Leukemia: State-of the-(C)ART and Road Ahead. Blood Adv. 2023.
. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2023;21(2):68-75.
. Gastric Myeloid Sarcoma. ACG Case Rep J. 2023;10(9):e01137.
. Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results. Biol Blood Marrow Transplant. 2019.
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019.
Risk Factors for Development of and Progression of Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome. Biol Blood Marrow Transplant. 2019.
. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019;17(12):686-696.
.